| Literature DB >> 17480239 |
Ross Bailie1, Damin Si, Michelle Dowden, Lynette O'Donoghue, Christine Connors, Gary Robinson, Joan Cunningham, Tarun Weeramanthri.
Abstract
BACKGROUND: Indigenous Australians experience disproportionately high prevalence of, and morbidity and mortality from diabetes. There is an urgent need to understand how Indigenous primary care systems are organised to deliver diabetes services to those most in need, to monitor the quality of diabetes care received by Indigenous people, and to improve systems for better diabetes care.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17480239 PMCID: PMC1876220 DOI: 10.1186/1472-6963-7-67
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Figure 1Distribution of 12 participating community health centres in the Top End of the Northern Territory, Australia.
Figure 2Follow-up of participants over the study period.
Characteristics of clinical record audit sample at baseline (N = 295)
| Characteristic | Number (%), mean ± SD or median (interquartile range) |
| Median age (range), years | 48 (16–87) |
| Men | 116 (39%) |
| Median duration of diabetes*, years | 5.7 (2.6, 8.7) |
| Current smokers | 107 (36%) |
| Diagnosis of hypertension in medical record | 140 (47%) |
| Diagnosis of hyperlipidaemia in medical record | 84 (28%) |
| Any microvascular complications† | 124 (42%) |
| Any macrovascular complications‡ | 57 (19%) |
| Medical comorbid conditions§ | |
| 0 | 86 (29%) |
| 1 | 81 (27%) |
| 2 | 63 (21%) |
| 3 | 43 (15%) |
| 4+ | 22 (8%) |
| Attended health centre in last 3 months | 226 (77%) |
| Attended health centre in last 12 months | 270 (92%) |
| Reasons for last attendance during prior 12 months | |
| Chronic illness care | 164 (61%) |
| Acute care | 88 (33%) |
| Sexual health or immunisation | 18 (6%) |
* Exclude 85 patients (29% of the total sample) whose date of diagnosis of diabetes was not documented in medical record.
† Microvascular complications include any retinopathy, nephropathy, neuropathy, renal disease, foot ulcer or amputation noted in the medical record.
‡ Macrovascular complications include any coronary artery disease or stroke noted in the medical record.
§ Medical comorbid conditions include hypertension, hyperlipidaemia, or any micro and macrovascular complications mentioned above.
Changes in levels of system development over study period (Assessment of Chronic Illness Care scores, potential range 0–11)
| Organisational influence | 3.4 (2.5, 4.3) | 5.2 (4.5,5.3) | 6.1 (4.5, 6.7) | ||
| External linkages | 4.8 (4.0, 5.6) | 5.4 (4.6, 6.0) | 6.5 (5.3, 7.8) | +0.6 (0.089) | |
| Self-management support | 3.8 (3.0, 3.9) | 5.3 (4.2. 5.8) | 6.4 (4.9, 7.3) | ||
| Decision support | 4.7 (4.0, 5.0) | 5.8 (4.7, 6.3) | 7.2 (5.8, 8.2) | +1.1 (0.077) | |
| Delivery system design | 4.5 (3.6, 5.2) | 5.9 (5.3, 6.7) | 7.2 (5.8, 8.2) | ||
| Clinical Information systems | 5.4 (4.6, 5.9) | 5.9 (5.3, 7.3) | 7.7 (6.1, 8.3) | ||
| Integration | 2.5 (1.9, 3.5) | 4.5 (3.5, 5.4) | 5.1 (4.1, 6.5) | ||
| Overall (Total) | 4.3 (3.4, 4.7) | 5.6 (4.6, 6.0) | 6.1 (5.6, 7.3) | ||
* P values are for Wilcoxon matched pairs signed rank sum tests. Changes significant at 0.05 level are shown in bold.
Examples of strategies and actions implemented by participating community health centres to improve services and systems
| ▪ Dedicated new Medicare officer time to process Medicare claims |
| ▪ Prepared for the Australian General Practice Accreditation Limited (AGPAL) accreditation |
| ▪ Secured financial resources to fund a new nurse position |
| ▪ Lobbied to recruit a program coordinator to coordinate chronic illness care |
| ▪ Developed a business plan including specific chronic illness care goals |
| ▪ Increased support from the regional Quality Improvement Coordinator to implement quality plans |
| ▪ Increased efficiency in claiming for Medicare funded items, with funds then used to support operation and maintenance of the computerised information system |
| ▪ In conjunction with schools, Women's Centres, community stores or takeaways, ran chronic disease prevention programs |
| ▪ Held regular meetings with new formed health advisory committee of Aboriginal elders, facilitating community input into health centre operation. The committee was also consulted to provide leadership and direction of community-based health activities |
| ▪ Funded new community development positions with the health centre assisting with networking in the community and working on prevention |
| ▪ Supported community-based initiatives, such as 'Water Aerobics' |
| ▪ Assisted visiting nutritionist in organising the healthy lunch program in the community, and meal design and preparation for the Aged Care Centre |
| ▪ Designated health centre time for community work on Friday am |
| ▪ Organised an event titled "No Drug, No Violence, No Alcohol " in the community, and offered incentives, such as a return airfare to Darwin (donated by Qantas), to promote behaviour changes |
| ▪ Ran a Diabetes Health Day in the community to improve clients' understanding of their conditions |
| ▪ Supported the Nutrition Worker based at the community store to provide healthy foods |
| ▪ Identified and established a list of outside services, names, and contact numbers to assist all staff to contact services and to help patients use them |
| ▪ Designated chronic disease nurses to provide self-management support |
| ▪ Implemented written care plans which contained patient goals agreed between clinicians and patients. These goals were reviewed during each visit |
| ▪ Developed key local language concepts |
| ▪ Arranged visiting mental health team (4 times/year) to assist with behaviour change interventions |
| ▪ Helped setting up a Diabetes Action group in the community |
| ▪ Designed oral guidelines and pictures to disseminate self-management knowledge and skills |
| ▪ Enhanced smoking cessation services supported by pharmacy and availability of patches for nicotine replacement treatment |
| ▪ Addressed concerns of patients and families through existing peer support groups at the Women's Centre in the community |
| ▪ Provided diabetes patients with blood glucose self-monitoring materials |
| ▪ Showed patients a food box (designed by a nutritionist) as an education tool to support individuals and families about what type of food is good for managing chronic disease |
| ▪ Organised patient peer groups to share their stories about care, for example, buying a scrubbing brush to clean feet, rubbing feet with cream, wearing shoes, and buying good tucker from the store |
| ▪ Supplied sharps containers for insulin dependent patients to safely dispose of needles |
| ▪ Educated patients on general safe storage of medications |
| ▪ Organised patient eduction delivered by the visiting Diabetes Educator from the Healthy Living NT |
| ▪ Provided training for primary care team by visiting specialists (eg physicians) |
| ▪ Developed chronic disease flow sheet based on clinical guidelines (the CARPA) |
| ▪ Organised chronic disease days with presence of specialist providers |
| ▪ Designated chronic disease nurses to implement planned visits and group visits, eg facilitating patients seeing multiple providers in a single visit |
| ▪ Developed and implemented cross culture education and training programs for staff |
| ▪ Held regular team meetings to revise and reinforce team roles |
| ▪ Used registers to identify active and non-active participation of patients, analysed reasons for non-active participation, and took measures to improve |
| ▪ When the doctor was visiting, Aboriginal health workers went out and talked to patients, and brought them into the health centre |
| ▪ Put a sign up at the community shop for doctor's and physician's visits, and picked up people if necessary |
| ▪ Arranged for patients to see specialists (eg ophthalmologists) in the regional centre, and transported them to their appointments |
| ▪ Utilised interpreters provided by the Aboriginal Resource and Development Services |
| ▪ Went out twice a day to give medications to patients in the community |
| ▪ The health team met regularly every morning to do handover and assign responsibility for patient follow-up |
| ▪ Commenced the use of case conferencing for patients with complex conditions and to assign responsibilities to PHC team members |
| ▪ One afternoon a week was set aside to do home visits for patients with major chronic conditions, and documenting relevant information in the medical records |
| ▪ Appointed the Health Centre Coordinator as team leader to ensure roles and responsibilities in chronic illness care |
| ▪ Implemented a new electronic system (based on File Maker Pro) for recording of services, follow-up and reminding |
| ▪ Performed a complete history notes audit and reorganised all individual files |
| ▪ Installed a new computerised clinical information system, providing functions such as medical record-keeping, intelligent recalls, and featured appointments |
| ▪ Developed and utilised a spreadsheet system with a list of people for follow-ups of 3 monthly bloods and the doctor's follow-ups of any abnormal findings |
| ▪ Linked the health centre information system ("Communicare") with the regional information system "Health |
Changes in processes of diabetes care
| Weight | 3 | 47 (41, 53) | 43 (37, 49) | 61 (54, 67) | 0.90 (0.72, 1.10) | |
| Height | Any time | 32 (27, 38) | 48 (42, 55) | 71 (65, 76) | ||
| BMI | 12 | 16 (12, 21) | 21 (16, 26) | 46 (40, 53) | 1.24 (0.84, 1.76) | |
| Waist circumference | 3 | 23 (18, 28) | 28 (23, 34) | 54 (48, 60) | 1.28 (0.92, 1.70) | |
| BP | 3 | 63 (57, 69) | 63 (56, 68) | 76 (71, 82) | 0.94 (0.76, 1.10) | |
| Visual acuity | 12 | 40 (35, 46) | 42 (36, 48) | 58 (52, 65) | 1.06 (0.83, 1.31) | |
| Cataracts | 12 | 28 (23, 34) | 35 (29, 41) | 24 (19, 30) | 1.31 (0.97, 1.68) | 0.80 (0.58, 1.08) |
| Fundi (dilated pupils) | 12 | 34 (29, 40) | 36 (30, 42) | 30 (25, 37) | 1.10 (0.83, 1.39) | 0.90 (0.68, 1.15) |
| Ophthalmologist review | 24 | 34 (29, 40) | 41 (34, 47) | 54 (48, 61) | 1.28 (0.99, 1.57) | |
| Check done | 3 | 20 (16, 25) | 24 (19, 29) | 58 (51, 64) | 1.23 (0.84, 1.72) | |
| Sensation | 3 | 9 (6, 13) | 12 (8, 16) | 48 (41, 54) | 1.49 (0.87, 2.46) | |
| Peripheral pulses | 3 | 8 (5, 12) | 13 (9, 17) | 48 (42, 54) | ||
| Pressure areas | 3 | 7 (5, 11) | 11 (7, 16) | 44 (38, 51) | 1.78 (0.99, 3.06) | |
| Infections | 3 | 8 (6, 12) | 12 (8, 17) | 27 (22, 33) | 1.64 (0.95, 2.69) | |
| BSL (finger prick or venous) | 3 | 61 (55, 67) | 51 (44, 57) | 69 (63, 74) | 1.13 (0.97, 1.27) | |
| HbA1c | 6 | 41 (35, 47) | 61 (55, 67) | 74 (68, 80) | ||
| Total cholesterol | 12 | 56 (50, 62) | 70 (64, 76) | 74 (68, 79) | ||
| Urine – Dipstix | 3 | 20 (15, 25) | 24 (19, 30) | 48 (42, 55) | 1.29 (0.93, 1.74) | |
| Creatinine | 12 | 65 (59, 71) | 68 (62, 74) | 74 (69, 80) | 1.03 (0.88, 1.16) | |
| ACR | 12 | 54 (48, 59) | 54 (47, 60) | 61 (55, 67) | 0.99 (0.80, 1.16) | 1.15 (0.99, 1.31) |
| Diet | 3 | 15 (11, 19) | 23 (18, 29) | 36 (30, 42) | ||
| Activity | 3 | 13 (9, 17) | 22 (17, 27) | 37 (31, 43) | ||
| Smoking | 3 | 10 (7, 14) | 21 (16, 26) | 30 (25, 37) | ||
| Alcohol | 3 | 9 (6, 13) | 21 (16, 27) | 33 (27, 39) | ||
| Diabetes medications | 3 | 10 (7, 14) | 26 (21, 32) | 36 (30, 42) | ||
| Influenza vaccination | 12 | 54 (48, 59) | 47 (41, 53) | 83 (78, 87) | 0.83 (0.65, 1.01) | |
| Pneumococcal vaccination | 5 yrs | 73 (68, 78) | 72 (66, 77) | 80 (74, 85) | 0.91 (0.73, 1.06) | 1.10 (0.99, 1.18) |
† Calculated by using multilevel logistic regression models with adjustment for health centre clustering and repeated measurements within the same individuals, and by converting odds ratios into risk ratios using a published formula. Risk ratios significant at 0.05 level are shown in bold.
Changes in pharmacological treatment rates over the study period
| Any insulin use | 10% (29/295) | 11% (29/253) | 10% (24/252) | 1.17 (0.96, 1.40) | 0.97 (0.79, 1.19) |
| Oral hypoglycaemic agents only | 69% (203/295) | 72% (181/253) | 71% (180/252) | 1.05 (0.83, 1.21) | 1.08 (0.92, 1.20) |
| Hypertension on treatment | 78% (112/143) | 89% (111/125) | 75% (119/159) | 0.96 (0.79, 1.09) | |
| Albuminuria on ACE inhibitor | 85% (129/151) | 85% (124/146) | 72% (114/158) | 1.02 (0.86, 1.11) | 0.87 (0.69, 1.00) |
| Hyperlipidemia on statin | 71% (99/140) | 83% (128/154) | 67% (98/146) | 0.93 (0.75, 1.09) | |
| Coronary heart disease/stroke on aspirin | 56% (32/57) | 60% (30/50) | 70% (30/43) | 1.00 (0.46, 1.47) | 1.30 (0.85, 1.59) |
| Aspirin use among diabetes patients without cardiovascular events but with one or more other cardiovascular risk factors* | 31% (53/173) | 55% (91/165) | 55% (101/184) |
* Other cardiovascular risks refer to hypertension, hyperlipidemia and smoking.
† Risk ratios significant at 0.05 level are shown in bold.
Frequency of elevated HbA1c and blood pressure results followed by documentation of review by a doctor and medication change over the study period
| HbA1c recorded in previous 12 months* | 291 | 296 | 317 | ||
| Elevated HbA1c† (%) | 173 (59%) | 179 (60%) | 169 (53%) | 1.02 (0.89, 1.16) | 0.90 (0.78, 1.03) |
| Reviewed by a doctor (%) | 45 (26%) | 82 (46%) | 4 (2%) | ||
| Medication adjusted (%) | 18 (10%) | 43 (24%) | 5 (3%) | ||
| BP recorded in previous 12 months* | 615 | 559 | 588 | ||
| Elevated BP† (%) | 145 (24%) | 154 (28%) | 151 (26%) | 1.17 (0.96, 1.42) | 1.09 (0.89, 1.33) |
| Reviewed by a doctor (%) | 30 (21%) | 62 (40%) | 5 (3%) | ||
| Medication adjusted (%) | 19 (13%) | 33 (21%) | 5 (3%) | 1.64 (0.98, 2.74) |
* As multiple HbA1c and BP results might be documented in the medical record for each patient in previous 12 month period, we only collected, when available, the two most recent HbA1c results and the three most recent BP results for each audit interval.
† Elevated HbA1c was defined as HbA1c > 8.0%. Elevated BP was defined as BP > 140/90 mmHg.
‡ Risk ratios significant at 0.05 level are shown in bold.
Changes in intermediate patient outcomes over the study period
| Mean HbA1c level (%) | 9.3 (8.8, 9.8) | 8.9 (8.3, 9.4) | 8.9 (8.6, 9.3) | ||
| HbA1c < 8% | 37 (28, 46) | 40 (30, 50) | 46 (40, 52) | 1.18 (0.79, 1.61) | |
| HbA1c < 7% | 19 (13, 24) | 21 (13, 29) | 28 (22, 34) | 1.16 (0.58, 2.09) | |
| Mean systolic BP | 130 (127, 133) | 131 (128, 135) | 130 (126, 133) | 2.3 (-0.6, 5.2) | -0.2 (-3.2, 2.8) |
| Mean diastolic BP | 79 (77, 82) | 79 (77, 82) | 79 (76, 81) | 0.4 (-1.6, 2.3) | -0.3 (-2.1, 1.4) |
| BP < 140/90 | 65 (58, 72) | 59 (51, 67) | 67 (61, 73) | 0.84 (0.66, 1.02) | 1.04 (0.90, 1.17) |
| BP < 130/80 | 33 (25, 41)) | 33 (23, 43) | 29 (22, 36) | 0.97 (0.69, 1.29) | 0.80 (0.57, 1.10) |
| Mean total cholesterol level | 4.9 (4.7, 5.1) | 4.9 (4.6,5.2) | 4.9 (4.6, 5.3) | -0.01 (-0.2, 0.2) | -0.06 (-0.3, 0.2) |
| Total cholesterol < 5.5 | 73 (66, 80) | 73 (64, 82) | 73 (63, 84) | 1.00 (0.77, 1.17) | 1.02 (0.82, 1.16) |
| Total cholesterol < 4.0 | 22 (16, 28) | 24 (17, 31) | 30 (19, 41) | 1.22 (0.68, 1.97) | 1.58 (0.95, 2.35) |
| Median ACR level * | 18.0 (3.7, 63.9) | 19.6 (3.5, 83.2) | 18.7 (4.8, 67.2) | P = 0.49 | P = 0.32 |
| ACR ≤ 3.4 | 21 (13, 29) | 24 (13, 35) | 18 (13, 23) | 0.93 (0.42, 1.78) | 0.76 (0.35, 1.46) |
| 3.4 < ACR ≤ 34 | 41 (33, 49) | 33 (24, 42) | 43 (35, 51) | 0.73 (0.43, 1.11) | 1.05 (0.72, 1.40) |
| ACR > 34 | 38 (29, 47) | 43 (30, 56) | 39 (30, 48) | 1.60 (0.92, 2.16) | 1.13 (0.67, 1.63) |
* Figures in this row are medians (interquartile ranges). P values indicate statistical significance based on Wilcoxon-Mann-Whitney test for non-parametric group comparison.
† Calculated by using multilevel regression models with adjustment for health centre clustering and repeated measurements within the same individuals, and by converting odds ratios into risk ratios when appropriate using a published formula. While the data for duration of diabetes were not sufficiently complete to allow for adjustment in the analysis (29% of participants had no date of diabetes diagnosis documented in medical records), additional adjustment for age did not significantly change the results. Therefore, we presented the data with no adjustment for age and duration of diabetes in this table. Mean differences or risk ratios significant at 0.05 level are shown in bold.